Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459912 · ClinicalTrials.gov registry record · Phase 2
Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02459912 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 1 participants.
The verdict
NCT02459912, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Men with low-risk, clinically localized, unilateral prostate cancer will be treated with unilateral nerve-sparing cryoablation and evaluated for the rate of potency, cancer control and health related quality of life outcomes after treatment.
Interventions
- PROCEDURE Unilateral Nerve-Sparing Cryoablation of the Prostate
- DEVICE Precise Cryoablation System with IceRod Needles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459912
The ClinicalTrials.gov registry entry for NCT02459912 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unilateral Nerve-Sparing Cryoablation of the Prostate is the first listed.
NCT02459912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459912 about?
NCT02459912 is a clinical study titled "Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer". Men with low-risk, clinically localized, unilateral prostate cancer will be treated with unilateral nerve-sparing cryoablation and evaluated for the rate of potency, cancer control and health related quality of life outcomes after treatment.
What is the current status of trial NCT02459912?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-04. Estimated completion is 2018-04-26.
What interventions are being tested in trial NCT02459912?
The interventions under investigation include: Unilateral Nerve-Sparing Cryoablation of the Prostate (PROCEDURE), Precise Cryoablation System with IceRod Needles (DEVICE).
Who is sponsoring clinical trial NCT02459912?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.